- Reports: ESI may start 'price war' over new hepatitis C drugs
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- FDA approves Upsher-Smith's Qudexy XR extended-release capsules
- Senate passes Drug Quality and Security Act
- More than half of drugs approved in 2013 were specialty, according to FDA
SILVER SPRING, Md. — The Food and Drug Administration will host a public meeting in March to discuss updating the OTC monograph system, the Wall Street Journal reported Friday.
According to the report, the FDA will consider improving the agency's ability to initiate label changes quickly, allowing for faster innovation from manufacturers and imposing new pediatric dosing limits based on the most recent science.
"We want to get the word out that we're looking for creative ideas about how to improve the process," Janet Woodcock, director of the FDA's center for drug evaluation, told WSJ.
The meeting will take place March 25 and 26.